In COPD, Mepolizumab Appears to Reduce the Need for Systemic Corticosteroids
Mepolizumab reduced all tested measures of systemic corticosteroid (SCS) use for any cause, as well as in response to acute exacerbation of COPD (AECOPD),...
Dupilumab Improves Patient-Reported COPD Outcomes
Dupilumab (Sanofi and Regeneron Pharmaceuticals, Inc.) enables patients with COPD and type 2 inflammation to avoid poor outcomes, according to results of a study...
Dupilumab Appears to Provide Quick Relief in COPD and Type 2 Inflammation
Dupilumab quickly alleviates patient-reported symptoms in people with COPD and type 2 inflammation, new pooled data from the BOREAS and NOTUS randomized controlled trials...
Brensocatib Improves Outcomes in Asian Patients With Bronchiectasis
Brensocatib reduced non-cystic fibrosis bronchiectasis exacerbations, improved symptoms, and slowed lung function decline among Asian patients, according to a post hoc analysis of data...